No Data
No Data
Pinning Down Prothena Corporation Plc's (NASDAQ:PRTA) P/S Is Difficult Right Now
It's not a stretch to say that Prothena Corporation plc's (NASDAQ:PRTA) price-to-sales (or "P/S") ratio of 12.3x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in t
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Buy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic Partnerships
Prothena (PRTA) Receives a Buy From Piper Sandler
No Data